Neutrophil gelatinase-associated lipocalin and end-stage renal disease: It is not all about the kidneys!

European Journal of Clinical Investigation

Volumn 43, Issue 8, 2013, Pages 816-820

  Rau, Simon ^a   Habicht, Antje ^b   Kauke, Teresa ^a   Hillmer, Andreas ^b   Wessely, Matthias ^a   Stangl, Manfred ^a   Guba, Markus ^a   Fischereder, Michael ^a   Schönermarck, Ulf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

End stage renal disease; Haemodialysis; Nephrectomy; Neutrophil gelatinase associated lipocalin

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; HUMAN; INFLAMMATION; KIDNEY AGENESIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE CELL; NEPHRECTOMY; PRIORITY JOURNAL;

EID: 84880722767     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12110     Document Type: Article

References (23)

1. Sengelov H, Kjeldsen L, Diamond MS, Springer TA, Borregaard N. Subcellular localization and dynamics of Mac-1 (alpha m beta 2) in human neutrophils. J Clin Invest 1993;92:1467-76.
2. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 1999;31:433-41.
3. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;52:595-605.
4. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-8.
5. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006;105:485-91.
6. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006;26:287-92.
7. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006;6:1639-45.
8. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 2008;108:c176-81.
9. Nickolas TL, Forster CS, Sise ME, Barasch N, Sola-Del Valle D, Viltard M et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int 2012; 82: 718-22.
10. Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007;22:101-8.
11. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010;120:4065-76.
12. Ding H, He Y, Li K, Yang J, Li X, Lu R et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007;123:227-34.
13. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2577-84.
14. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 2007;27:373-8.
15. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008;23:414-6.
16. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337-44.
17. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007;71:967-70.
18. Malyszko J, Malyszko JS, Koc-Zorawska E, Kozminski P, Mysliwiec M. Neutrophil gelatinase-associated lipocalin in dialyzed patients is related to residual renal function, type of renal replacement therapy and inflammation. Kidney Blood Press Res 2009;32:464-9.
19. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-56.
20. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 2012;1826:129-69.
21. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
22. Bhavsar NA, Kottgen A, Coresh J, Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and Kidney injury molecule 1 (KIM-1) as Predictors of Incident CKD Stage 3: the Atherosclerosis risk in communities (ARIC) Study. Am J Kidney Dis 2012; 60: 233-40.
23. Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. Ren Fail 2008;30:625-8.